The Zhitong Finance App learned that Weilizhibo-B (09887) rose by more than 5%. As of press release, it had risen 4.06% to HK$36.36, with a turnover of HK$9.552 million.
According to the news, on October 26, Velizibo-B announced that updated clinical and translational data from the four studies of Vilisin ® (opatisumimab, PD-L1/4-1BB bispecific antibody) were presented at the 2026 European Society of Medical Oncology Annual Meeting (2026 ESMO). The publication of these reports includes the latest breakthrough summary (LBA) oral report on Verisign ® single-agent treatment of third-line or posterior-line extrapulmonary neuroendocrine cancer (EP-NEC); selected oral report on Velisign® combined chemotherapy first-line treatment of EP-NEC; a poster presentation on Verisign® combined chemotherapy first-line treatment of biliary tract cancer (BTC); and Verisin® treatment of microsatellite-stabilized (MSS) junction Translational research on rectal cancer (CRC) poster presentation.
Velisign ® is a bispecific antibody that targets both PD-L1 and 4-1BB, and has the potential to become a pan-tumor IO 2.0 cornerstone therapy with survival benefits. Currently, Verisign ® has carried out clinical studies for 14 indications, including 1 single-arm critical registration clinical study, 1 confirmatory phase III clinical study, and 9 proof-of-concept studies, covering multiple major cancer types and “cold tumors”. Among the 7 types of cancer supported by clinical data, Verisign ® has shown excellent clinical value and broad treatment prospects, including extrapulmonary neuroendocrine cancer (EP-NEC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC), and ovarian cancer (OC).